Ablynx Announces Interim Results Of First Nanobody(R) Phase I Study Of ALX- 0081 (ANTI-VWF)

GHENT, Belgium, 2 July, 2007 -- Ablynx today announced positive interim results from the ongoing Phase I study of its lead development programme, ALX-0081, an anti-thrombotic treatment. ALX-0081 is a novel ‘first-in-class’ therapeutic Nanobody® targeting von Willebrand Factor (vWF), which can reduce the risk of thrombosis in patients with acute coronary syndrome.

MORE ON THIS TOPIC